Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.
The most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators, proteasome inhibitors, etc. The VTD (bortezomib, thalidomide, and dexamethasone) and TD (thalidomide and dexamethasone) regimens are commonly used as a first-line treatment due to limited resources. The study aimed to compare the proportion of favorable responses, survival, and time to the next treatment between two different treatment approaches. The investigators designed a retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.
Study Type
OBSERVATIONAL
Enrollment
83
Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)
Hospital General de Mexico Dr. Eduardo Liceaga
Mexico City, Mexico City, Mexico
RECRUITINGFavorable Response
Criteria established with the International Multiple Myeloma Working Group
Time frame: Post-induction (6 months)
Time to next treatment
Need for a secondline treatment after induction
Time frame: Post-induction (2 years)
Overall survival
Survivorship passing 3000 days
Time frame: 3000 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.